Remove Access Remove Clinical Trials Remove Cultivation Remove Data
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

Press Release: Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Cannabis Law Report

All Optimi mushroom products are grown from the Company’s world-leading psilocybin genetic bank and are grown in EU-GMP compliant clean rooms that ensure sterile cultivation and undergo almost 300 different analytical tests post-harvest. To access a complete photo gallery of this historic grow, please click here. Penis Envy.

History 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.

DEA 133
article thumbnail

Press Release: Canada – Princeton mushroom research and development facility officially opens, sells first grow of psilocybin mushrooms

Cannabis Law Report

A new cultivation facility that is hoping to change lives with psychedelic mushrooms had their grand opening on Friday in Princeton, after being awarded a dealer’s license in February by Health Canada. And there are literally hundreds of trials that are being done, and more forthcoming.”. Optimi Health Corp.

article thumbnail

New Zealand Govt Consultation Doc Says “Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand”

Cannabis Law Report

This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis. The consultation covers proposed licensing, cultivation, manufacturing and product standards, and a prescription and enforcement regime. From trial to market.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis.

article thumbnail

Jones Day: The life sciences regulatory regime in Australia

Cannabis Law Report

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.